secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2026-08-03T11:07:36+00:00
Accession:  0001104659-26-089443
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q2 2026 net loss $78.8M; AXPAXLI NDA on track for Q4 2026
----------------------------------------------------------------------------

- Net loss of $78.8M ($0.35 per share) for Q2 2026, vs. $67.8M loss in Q2 2025.
- Cash balance $598.6M as of June 30, 2026; expected runway into 2028.
- AXPAXLI NDA submission for wet AMD planned for Q4 2026 after FDA Type C meeting alignment.
- Post-hoc SOL-1 analysis shows up to 72% reduction in treatment burden vs. aflibercept (2 mg) over 60 weeks.
- DEXTENZA revenue flat at $13.5M; R&D expenses $54.1M, up from $51.1M in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/0001104659-26-089443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-089443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer